Viatris Inc

Viatris Inc. is a U.S.-based global pharmaceutical company that develops, manufactures, and distributes branded medicines, generic medicines, and complex products. Its business is organized across Developed Markets, Greater China, JANZ, and Emerging Markets, with operations spanning more than 165 countries and territories.

0,9 %

35,1 %

−24,6 %

−3,0 %

1.38

0.82

— Viatris Inc
%
Branded medicines35% Established prescription brands sold in developed and emerging markets.
Generic medicines40% Off-patent medicines, including complex generics and first-to-file launches.
Complex and specialty products15% Harder-to-make products such as inhalers, injectables, and other complex dosage forms.
Emerging market and regional portfolios10% Localized branded and generic medicines sold across developing markets and Asia.

Viatris sells primarily into the pharmaceutical distribution chain, including wholesalers, retail drug chains,...

  • Drug wholesalers and retail drug chainsprimary

    Buy large volumes of prescription medicines for downstream pharmacy distribution and price-sensitive access.

  • Government and institutional buyersprimary

    Purchase medicines for public health systems, hospitals, and reimbursement programs.

  • Pharmacies and pharmacy networkssecondary

    Stock branded and generic products for retail dispensing and patient access.

  • Physicians and prescriberssecondary

    Influence demand for branded, specialty, and complex medicines through prescribing choices.

  • Managed care and buying groupssecondary

    Negotiate access, rebates, and formulary placement that affect product uptake.

Viatris is headquartered in the United States and operates through four geographic segments: Developed Markets, Greater...

  • •Headquartered in the United States with global centers in Pittsburgh, Shanghai, and Hyderabad
  • •Developed Markets covers North America and Europe
  • •Greater China includes mainland China, Taiwan, and Hong Kong
  • •JANZ covers Japan, Australia, and New Zealand
  • •Emerging Markets spans more than 125 countries across multiple regions

Viatris’ strategy centers on using its global scale, broad portfolio, and supply chain to serve patients across many...

01
Portfolio expansion and launchesshort-term

New products help offset lifecycle pressure on older medicines and broaden market coverage.

02
Pipeline developmentmedium-term

Innovative and first-to-market programs can create differentiated growth opportunities.

03
Global supply chain reliabilitymedium-term

Consistent manufacturing and distribution are essential in regulated pharmaceutical markets.

04
Technology and operating modernizationmedium-term

Better data, systems, and talent support execution across a complex global footprint.

Viatris faces pricing pressure, customer concentration, regulatory scrutiny, and litigation risk typical of large...

high

Customer concentration

A limited number of large customers account for a meaningful share of sales, so lost business would materially affect revenue and cash flow.

Scope
Top three customers represented about 25% of net sales in 2025
Materiality
high
high

Pricing and reimbursement pressure

Wholesalers, retail chains, and managed care organizations have increasing bargaining power, which can compress realized prices and rebates.

Scope
U.S. and Europe, where pricing and reimbursement are highly competitive
Materiality
high
high

Patent and intellectual property litigation

Generic and complex-generic launches can trigger infringement claims and delay commercialization.

Scope
At-risk launches and first-to-file opportunities
Materiality
high
high

Regulatory and compliance risk

Pharmaceutical products are heavily regulated, and violations can lead to delays, penalties, or product restrictions.

Scope
Global manufacturing, approvals, and distribution
Materiality
high
medium

Foreign exchange and international exposure

Revenue and costs are spread across many currencies and jurisdictions, creating translation and transaction risk.

Scope
More than 165 countries and territories
Materiality
medium
Revenue deductions and variable consideration
Net sales and receivables
Goodwill and intangible asset impairment
Operating income and equity
Acquisition-related amortization and fair value adjustments
Adjusted and reported earnings
Legal contingencies
Expenses and liabilities
Income taxes
Tax expense and cash taxes

ELITE PHARMACEUTICALS INC /NV/

ELTP · Pharmaceutical Preparations

Kairos Pharma, LTD.

KAPA · Pharmaceutical Preparations

GoodRx Holdings, Inc.

GDRX · Services-Computer Processing & Data Preparation

MIRA PHARMACEUTICALS, INC.

MIRA · Pharmaceutical Preparations

ELI LILLY & Co

LLY · Pharmaceutical Preparations

Ventyx Biosciences, Inc.

Pharmaceutical Preparations

: 11/08/2026